OVOCA BIO PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 EUR | -.--% |
|
-.--% | -.--% |
| 2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Ovoca Bio Plc is a biopharmaceutical company specialized in the development and manufacturing of peptides for the treatment of female sexual dysfunction.
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Calendar
2024-06-27
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.73% | 22.15B | |
| -17.37% | 21.02B | |
| -8.86% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- OVXA Stock
- OVXA Stock
- News Ovoca Bio plc
- Ovoca Bio Up 43% After Russia Approves Orenetide
